How can diagnostic laboratories accelerate the clinical adoption of allogeneic cell therapies?
This interview from our sister site, Bioanalysis Zone, is based on a recent overview article published by members from the College of American Pathologists Personalized Healthcare Committee and the Histocompatibility and Identity Testing Committee, who conducted a scoping literature review to better understand the most significant challenges of allogeneic cell therapy for laboratory medicine and pathology.
Dr Matthew Anderson and Dr Fabienne Lucas (both members of the College of American Pathologists’ Allogeneic Cell Therapy Project Team) explore the role of surrogate biomarkers in assessing the persistence and efficacy of allogeneic cell therapies, highlighting the challenges in developing reliable, standardized biomarkers. They also provide their insights on emerging technologies and the importance of cross-disciplinary collaboration to overcome current limitations and improve the clinical application of allogeneic cell therapies.